To qualify for Semaglutide GLP-1, patients generally need to meet specific criteria related to their health and weight status
Beyond their role in addiction, GLP-1 receptor agonists are used in a range of medical conditions, including type 2 diabetes, obesity, cardiovascular disease, liver and kidney health, and emerging research in neurodegenerative disorders
Over the 40-week trial, participants saw a 1.7 to 2 percent decrease in A1Ca measure of average blood sugar levelswhile on retatrutide
This includes: Increasing insulin production: Ozempic increases the amount of insulin the pancreas produces by stimulating the hormone incretin after glucose consumption
In TRIUMPH-3, up to 13.5 percent of participants using retatrutide stopped early, compared with 4.8 percent taking a placebo
Wang, et al